story of the week
Datopotamab–Deruxtecan Plus Durvalumab for Early-Stage Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Nature Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
Nat. Med. 2024 Sep 14;[EPub Ahead of Print], RA Shatsky, MS Trivedi, C Yau, R Nanda, HS Rugo, M Davidian, B Tsiatis, AM Wallace, AJ Chien, E Stringer-Reasor, JC Boughey, C Omene, M Rozenblit, K Kalinsky, AD Elias, C Vaklavas, H Beckwith, N Williams, M Arora, C Nangia, ET Roussos Torres, B Thomas, KS Albain, AS Clark, C Falkson, DL Hershman, C Isaacs, A Thomas, J Tseng, A Sanford, K Yeung, S Boles, YY Chen, L Huppert, N Jahan, C Parker, K Giridhar, FM Howard, MM Blackwood, T Sanft, W Li, N Onishi, AL Asare, P Beineke, P Norwood, L Brown-Swigart, GL Hirst, JB Matthews, B Moore, WF Symmans, E Price, D Heditsian, B LeStage, J Perlmutter, P Pohlmann, A DeMichele, D Yee, LJ van 't Veer, NM Hylton, LJ EssermanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.